Inicio › Cáncer metastásico › Pensilvania
Ensayos clínicos de Cáncer metastásico en Pensilvania
68 estudios sobre Cáncer metastásico buscan participantes en Pensilvania.
Ciudades en Pensilvania
Texto oficial del estudio (inglés)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06943755Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC Altoona, Altoona
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- y 18 más
ReclutandoFase 2
Todas las edades · Todos los sexos · Actualizado el 29 sept 2026 · NCT05564377Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- UPMC Hillman Cancer Center, Pittsburgh
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT05803382A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07277413A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
ReclutandoFase 1
Edades de 19 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06586957Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Thomas Jefferson University, Philadelphia
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07562152A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
ReclutandoFase 1/2
Hasta los 25 · Todos los sexos · Actualizado el 25 sept 2026 · NCT04094610A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Fox Chase Cancer Center, Philadelphia
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT05118789Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06128551A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
- AHN Allegheny General Hospital, Pittsburgh
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07218380Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- Lankenau Medical Center, Paoli
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07028489SLV-154 Treatment of Advanced Cancers
- Fox Chase Cancer Center, Philadelphia
ReclutandoFase 1
Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06771219A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- St. Luke's University Health Network, Bethlehem
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
- University of Pennsylvania Hospital, Philadelphia
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07174336A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- University of Pittsburgh Medical Center, Pittsburgh
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07114601A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Pennsylvania Hospital, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07213804A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Thomas Jefferson University, Sidney Kimmel Comprensive Cancer Center, Clinical Trials Office, Philadelphia
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT07450859A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT06863272Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT06566079The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT04585750CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Pittsburgh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT07335497A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Alliance Cancer Specialists, PC, Horsham
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06119581Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
- UPMC Hillman Cancer Center, Pittsburgh
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT04585958AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Philadelphia
ReclutandoFase 1/2
Edades de 18 a 75 · Todos los sexos · Actualizado el 4 sept 2026 · NCT07038343Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- UPMC Hillman Cancer Center, Pittsburgh
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT05372614A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- Thomas Jefferson University Hospital, Philadelphia
ReclutandoFase 1/2
Edades de 18 en adelante · Mujeres · Actualizado el 3 sept 2026 · NCT04802759A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
- Sidney Kimmel Cancer Center, Philadelphia
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 sept 2026 · NCT07213817A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07029399A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
- Sidney Kimmel Cancer Center, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT06803680A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Asplundh Cancer Pavilion, Willow Grove
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT06769698FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute, Lancaster
- University of Pennsylvania, Philadelphia
- Thomas Jefferson University, Philadelphia
- y 2 más
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT05614739Pemefolacianine for IMI of Lung Cancer
- University of Pennsylvania, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT07772895FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05919264Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
ReclutandoFase 1
Edades de 12 en adelante · Todos los sexos · Actualizado el 31 jul 2026 · NCT05372640Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- UPMC Hillman Cancer Center, Pittsburgh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 31 jul 2026 · NCT05691491A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Philadelphia
- Crinetics Study Site, Philadelphia
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 31 jul 2026 · NCT07129252A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 jul 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Bethlehem
- Research Site, Hershey
- Research Site, Lancaster
- y 5 más
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 29 jul 2026 · NCT07044336Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #109, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jul 2026 · NCT06545942A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 jul 2026 · NCT06657144A Study of PYX-201 in Advanced Solid Tumors
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 jun 2026 · NCT05720117De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.